Search results for " low-density"

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidaemia: a randomized pilot tria

2013

Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open-label, blinded end point (PROBE) study (ClinicalTrials.gov identifier: NCT01010516). Patients (n = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) or to add-on-statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low-density lipoprotein (LDL) …

Upregulation of liver VLDL receptor and FAT/CD36 expressions in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid

2006

International audience; This study explores the mechanisms responsible for the fatty liver setup in mice fed trans-10,cis-12 conjugated linoleic acid (t10c12 CLA), hypothesizing that an induction of low density lipoprotein receptor (LDLR) expression is associated with lipid accumulation. To this end, the effects of t10c12 CLA treatment on lipid parameters, serum lipoproteins, and expression of liver lipid receptors were measured in LDLR(-/-) apoB(100/100) mice as a model of human familial hypercholesterolemia itself depleted of LDLR. Mice were fed t10c12 CLA over 2 or 4 weeks. We first observed that the treatment induced liver steatosis, even in the absence of LDLR. Mice treated for 2 weeks…

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation.

2015

Nonalcoholic fatty liver disease (NAFLD) is defined by excessive triglycerides (TGs) accumulation in the liver (>5% of hepatocytes histologically) in the absence of alcohol excess. The NAFLD ranges from simple steatosis to steatohepatitis and cirrhosis. The NAFLD and nonalcoholic steatohepatitis (NASH) are now the number one cause of liver disease in Western countries. The prevalence of NAFLD is increasing but is underreported, and the epidemiology and demographic characteristics vary worldwide. The prevalence is increasing because of the rising occurrence of obesity and type 2 diabetes (T2DM); in fact, NAFLD is considered as the hepatic manifestation of metabolic syndrome (MetS). Nonalcoho…

The chloro‐substituent enhances performance of 2,4‐bis (imino)pyridylchromium catalysts yielding highly linear polyethylene

2020

The five unsymmetrical 2‐[1‐(2,4‐dibenzhydryl‐6‐chlorophenylimino)ethyl]‐6‐[1‐(arylimino)ethyl]pyridine compounds (aryl: 2,6‐Me2Ph L1 , 2,6‐Et2Ph L2 , 2,6‐i Pr2Ph L3 , 2,4,6‐Me3Ph L4 and 2,6‐Et2–4‐MePh L5 ) were prepared and characterized with FT‐IR and 1H/13C NMR spectroscopy as well as elemental analysis. The treatment of L1 – L5 with CrCl3·3THF affords the corresponding chromium chloride complexes (Cr1 – Cr5 ) in excellent yields. The molecular structures of Cr2 and Cr3 characterized by X‐ray diffraction show a distorted octahedral geometry with three nitrogen atoms and three chlorine atoms around the metal center. On activation with either MAO or MMAO, Cr1 – Cr5 collectively display hig…

Changes in fatty acid compositions of total serum and lipoprotein particles, in growing rats given protein-deficient diets with either hydrogenated c…

1994

The present study examines the effects of dietary saturated (hydrogenated coconut oil) and polyunsaturated (salmon oil) fats on the composition and metabolism of lipoproteins in growing rats fed on protein-deficient diets. Four groups of rats were fed on the following diets for 28 d: 200 g casein+50 g coconut oil (COC)/kg, 20 g casein+50 g coconut oil (COd)/kg, 200 g casein + 50 g salmon oil (SAC)/kg, 20 g casein+50 g salmon oil (SAd)/kg. Both protein-deficient groups exhibited low concentrations of protein and triacylglycerol (in serum, very-low-density lipoprotein (VLDL), low-density lipoprotein-high-density lipoprotein, (LDL-HDL1) and HDL2-3), of cholesterol (in LDL-HDL1) and of phosphol…

Polypropylene and poly(ethylene-co-1-octene) effective synthesis with diamine-bis(phenolate) complexes: Effect of complex structure on catalyst activ…

2017

A series of group 4 metal complexes bearing amine-bis(phenolate) ligands with the amino side-arm donor: (μ-O)[Me2N(CH2)2N(CH2-2-O-3,5-tBu2-C6H2)2ZrCl]2 (1a), R2N(CH2)2N(CH2-2-O-3-R1-5-R2-C6H2)2TiCl2 (R = Me, R1, R2 = tBu (2a), R = iPr, R1, R2 = tBu (2b), R = iPr, R1 = tBu, R2 = OMe (2c)), and Me2N(CH2)2N(CH2-2-O-3,5-tBu2-C6H2)(CH2-2-O-C6H4)TiCl2 (2d) are used in ethylene and propylene homopolymerization, and ethylene/1-octene copolymerization. All complexes, upon their activation with Al(iBu)3/Ph3CB(C6F5)4, exhibit reasonable catalytic activity for ethylene homo- and copolymerization giving linear polyethylene with high to ultra-high molecular weight (600·× 103–3600·× 103 g/mol). The activi…

Ezetimibe with or without simvastatin increases small dense low-density lipoproteins in healthy men – a randomized trial

2010

Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter.

2004

To test for intrinsic differences in metabolic properties of low-density lipoprotein (LDL) as a function of particle size, we examined the kinetic behavior of 6 human LDL fractions ranging in size from 251 to 265 A injected intravenously into human apolipoprotein (apo) B transgenic mice. A multicompartmental model was formulated and fitted to the data by standard nonlinear regression using the Simulation, Analysis and Modeling (SAAM II) program. Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P.03), and there was a significant …

Familial combined hypolipidemia due to mutations in the ANGPTL3 gene

2013

The role of ANGPTL3 in lipoprotein metabolism emerged from studies in a mutant mouse strain characterized by severe hypotriglyceridemia and carrying a loss-of-function (LOF) mutation of the ANGPTL3 gene. ANGPTL3 was found to inhibit lipoprotein lipase and endothelial lipase. Genome-wide association studies in humans demonstrated the association of ANGPTL3 variants with plasma triglyceride levels and LOF mutations of ANGPTL3 were found in hypotriglyceridemic subjects in population studies. Recently, individuals originally classified as affected by familial hypobetalipoproteinemia were found to be homozygotes/compound heterozygotes for rare LOF mutations of ANGPTL3. They show a striking reduc…